Ken Griffin, the billionaire hedge fund manager, made significant investments in high-yield dividend stocks in the second quarter of 2024, despite not being an income investor himself with a net worth of $43 billion.
One notable purchase was his increased stake in Pfizer (NYSE: PFE), a big pharma company with a forward-dividend yield of 5.8%. Griffin added 7.89 million shares to Citadel’s holdings, marking a 63% increase and making Pfizer one of the hedge fund’s top positions.
Griffin’s interest in Pfizer stems from various factors, including the company’s attractive dividend yield, discounted valuation, and potential for long-term growth. His consistent accumulation of Pfizer shares over the past quarters indicates confidence in the company’s future prospects.
While following Griffin’s investment decisions isn’t a foolproof strategy, Pfizer could be an appealing option for value and income investors due to its undervaluation and strong dividend track record.
Investors considering Pfizer should weigh the company’s growth potential against other investment opportunities. While growth investors might seek higher-growth alternatives, value and income investors could find Pfizer’s current position favorable for long-term returns.
For those interested in exploring alternative investment options, it may be beneficial to consult resources like the Motley Fool Stock Advisor service, which offers insights into potential high-growth stocks that could outperform the market.
As with any investment decision, conducting thorough research and considering personal financial goals and risk tolerance is crucial before investing in any stock.
Billionaire Ken Griffin Loaded Up on This High-Yield Dividend Stock. Should You? was originally published by The Motley Fool